← Back
$PMN All transactions

ProMIS Neurosciences Inc.

▲ BUY
5 / 10

Conviction

$ Value

Shares

700,741

Price

Filed

Feb 5

Why this score? (5/10)
  • Open market buy (+3)
  • 10%+ owner (+1)
  • Not a 10b5-1 plan (+1)

Insider

Name

ABG Management Ltd.

Title

CIK

0001832106

Roles

10% Owner

Transaction Details

Transaction Date

2026-02-03

Code

P

Table

Derivative

Ownership

Indirect

Equity Swap

No

Shares After

700,741

Footnotes

The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share. | The Common Shares reported herein include: (i) 407,230 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) 206,100 Common Shares held of record by ABG V-SIV X Limited. | Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P. | Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited. | Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited. | The warrants to purchase Common Shares (the "Warrants") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the "Milestone Event" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310. | The Warrants reported herein include: (i) Warrants to purchase 164,881 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) Warrants to purchase 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) Warrants to purchase 206,100 Common Shares held of record by ABG V-SIV X Limited.

Filing Info

Accession No.

0001493152-26-005410

Form Type

4

Issuer CIK

0001374339

ABG Management Ltd.'s History

Date Ticker Type Value
2026-02-03 PMN $8.5M
2026-02-03 PMN
2025-10-22 PMN A $0

Other Insiders at PMN (90d)

Insider Bought Sold Last
ABG Management Ltd. $8.5M 2026-02-03
Kirwin Patrick D. $45K 2026-04-22
Kaplan Johanne
Chief Development Officer
$25K 2026-02-19
Warma Neil K
Chief Executive Officer
2026-02-03
Milbury Max A. 2026-02-03
Cashman Neil
Chief Scientific Officer
2026-02-03